NZ329311A - use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus - Google Patents

use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus

Info

Publication number
NZ329311A
NZ329311A NZ329311A NZ32931195A NZ329311A NZ 329311 A NZ329311 A NZ 329311A NZ 329311 A NZ329311 A NZ 329311A NZ 32931195 A NZ32931195 A NZ 32931195A NZ 329311 A NZ329311 A NZ 329311A
Authority
NZ
New Zealand
Prior art keywords
human milk
casein
mammalian cells
contained
infection
Prior art date
Application number
NZ329311A
Inventor
Pradip Mukerji
Amanda Eun-Yeong Seo
Steven Neal Anderson
Joseph Paul Schaller
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/249,554 external-priority patent/US5506209A/en
Priority claimed from US08/249,555 external-priority patent/US5538952A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from NZ283578A external-priority patent/NZ283578A/en
Publication of NZ329311A publication Critical patent/NZ329311A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

b-Casein contained in human milk, a recombinant form of b-casein contained in human milk or hydrolysates thereof is used in the manufacture of a medicament for inhibiting the infection of mammalian cells by RSV (Respiratory Syncytial Virus). b-Casein contained in human milk, a recombinant form of b-casein contained in human milk or hydrolysates thereof is used in the manufacture of a liquid nutritional product or an infant formula also containing at least one protein not contained in human milk for inhibiting the infection of mammalian cells by RSV. b-Casein contained in human milk, a recombinant form of b-casein contained in human milk or hydrolysates thereof is used in the manufacture of a enteral nutritional product also containing at least one protein not contained in human milk for treating and/or preventing respiratory tract infection in a mammal by inhibiting the infection of mammalian cells by RSV.
NZ329311A 1994-05-26 1995-03-27 use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus NZ329311A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/249,554 US5506209A (en) 1994-05-26 1994-05-26 Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US08/249,555 US5538952A (en) 1994-05-26 1994-05-26 Inhibition of infection of mammalian cells by respiratory syncytial virus
NZ283578A NZ283578A (en) 1994-05-26 1995-03-27 Nutritional product containing beta casein effective in preventing infection of human cells by respiratory syncytial virus

Publications (1)

Publication Number Publication Date
NZ329311A true NZ329311A (en) 2000-07-28

Family

ID=27353772

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ329311A NZ329311A (en) 1994-05-26 1995-03-27 use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus

Country Status (1)

Country Link
NZ (1) NZ329311A (en)

Similar Documents

Publication Publication Date Title
CA2122612A1 (en) Pharmaceutical products for curing tumourous diseases and process for preparing same
NZ215939A (en) Phosphonyl methoxyadenine antiviral compositions
SE9600233L (en) Use of a lactoperoxidase system for the preparation of a drug against Helicobacter pylori
CA2054358A1 (en) High acid nutritional formulations
DK0913156T3 (en) Use of activated protein C for the treatment of hypercoagulation conditions associated with sepsis
HU912064D0 (en) Process for the production of aralyphic n-substituted amino-alcane-phosphine acids and medical preparations containing them
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
PT914110E (en) METHOD OF MODULATING MICRO-CIRCULATION
HU910979D0 (en) Process for the prodiction of medical preparations with n-neuropeptide-antagonistic effect, containing guanidine derivatives
GR3025488T3 (en) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
US5543392A (en) Digestive tract cell activating agent of EGF and lactoferrin
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
MX9803565A (en) A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein.
IL102774A0 (en) Process for the preparation of human protein-containing,readily compatible medicaments for infusion or injection purposes
MX9605830A (en) Inhibition of infection of mammalian cells by respiratory syncytial virus.
JPS649938A (en) Oral ingestive composition
AU1158197A (en) Product for inhibition of attachment of h. influenzae to human cells
MX9605829A (en) Inhibition of attachment of h. influenzae to human cells.
JPS6455143A (en) Production of milk powder for nursing which is endowed with phylactic ability
MX9701979A (en) Inhibition of human rotavirus infection.
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
Ichikawa Protection of the surgical wound following plastic surgery and nursing care to maintain cleanliness of the regions--protection and preservation of the surgical wound following plastic surgery of cleft lip and palate and microtia
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
EP0192327A3 (en) Use of phosphonoformic acid and its esters and salts for the manufacture of a medicament for the treatment of AIDS
GR950100316A (en) Medicinal preparation based on fetal cell suspension, having immune substituting effect and method of treatment of acquired immune deficiency syndrome (HIV infection) with the use of said preparation.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)